Efficacy of levetiracetam in the treatment of pediatric epilepsy

Pang, Qiming; Li, Bangtao; Zhang, Suli; Li, Jiaoyang; Gu, Shuo

doi:10.1097/md.0000000000028882

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its effectiveness and good tolerance, levetiracetam has recently been increasingly used as a drug of first choice–monotherapy in the treatment of epileptic seizures, especially focal and bilateral clonic-tonic seizures. Numerous studies confirmed a significant reduction of seizures in children on polytherapy due to focal, myoclonic, generalized seizures and juvenile myoclonic epilepsy ( 10 ). It has also been shown to be effective treatment for patients in status epilepticus ( 11 , 12 ).…”

Section: Discussionmentioning

confidence: 94%

Efficacy and Safety of Levetiracetam for Childhood Epilepsies

Catibusic,

Uzicanin,

Salihbegovic

et al. 2024

Med Arch

View full text Add to dashboard Cite

Background: Levetiracetam (LEV) is a broad spectrum second-generation antiepileptic drug (AED). Objective: The objective of the study was to investigate the efficacy and safety of levetiracetam for childhood epilepsies. Methods: This is single, tertiary centre observational, prospective study, that included paediatric patients who were treated with levetiracetam at Paediatric hospital University Clinical Centre Sarajevo, during the period of 15 years (2008-2022). Inclusion criteria were: paediatric patients age > 1 month, diagnosed with epilepsy according to International League Against Epilepsy. After the introduction of levetiracetam, each patient has been followed up at least 12 months. According to the outcome the patients were divided into 5 groups: seizure reduction >50%, seizure reduction <50%, complete seizure freedom, the same number of seizures and increased number of seizures. From these groups two intergroups have been formed: responders (seizure reduction >50% and complete seizure freedom) and non-responders (seizure reduction <50%, the same number of seizures and increased number of seizures). Results The study enrolled 259 patients (141 female and 118 male), with mean age 7 years (3,0–12.0). Comorbidities were present at 129/259 (49.8%) patients. After 12 months of treatment, 25/259 (9.7%) patients had seizure reduction >50%, 30/259 (11.6%) patients had seizure reduction <50%, 154/259 (56.5%) patients had achieved seizure freedom, 31/259 (12%) patients had same number of seizures, while 19/259 (7.3%) patients had increased number of seizures. Seizure frequency between responders and non-responders, before treatment and after 12 months of treatment was statistically significant (p<0.001). Discussion: Non responders had the best outcome with ditherapy (30/79; 38%), while responders had the best outcome with monotherapy (161/180;89.4%). Conclusion: Levetiracetam is efficient antiepileptic drug for different types of epilepsies in childhood, used as mono, di or polytherapy.

show abstract

Section: Discussionmentioning

confidence: 94%

Efficacy and Safety of Levetiracetam for Childhood Epilepsies

Catibusic,

Uzicanin,

Salihbegovic

et al. 2024

Med Arch

View full text Add to dashboard Cite

show abstract

“…It has a unique site in the brain, which is the synaptic vesicle protein (SV2A), to act on achieving its antiepileptic effect. Levetiracetam regulates the function of SV2A by decreasing the vesicle release rate [ 19 ]. Intravenous levetiracetam can be given to patients who cannot tolerate oral levetiracetam, and its’ peak plasma concentration is reached in only 5-15 minutes.…”

Section: Discussionmentioning

confidence: 99%

Heterozygous Mutation of Sodium Voltage-Gated Channel Alpha Subunit 2 and Pumilio Homolog 1 Genes in a Pediatric Patient: A Case Report

Al-Sharif¹,

Attiah²,

AlKhateeb³

et al. 2022

Cureus

View full text Add to dashboard Cite

Epilepsy is a neurological condition brought on by recurrent and spontaneous seizures in patients with hypersynchronous neuronal ensemble activity. These spontaneous seizures appear to be brought on by increased neuronal excitability and synaptic synchronization. The development of neuronal hyperexcitability and acquiring epilepsy is still poorly understood. Cell differentiation and development might be related to the pumilio RNA-binding family member 1 (Pumilio 1 ( PUM1 )). Complete deficiency of this gene causes misregulation of the proteins involved in the control of neuronal excitability. Furthermore, the voltage-gated sodium channels alpha subunit 2 ( SCN2A ) triggers action potentials in brain neurons, and a variety of severe hereditary epilepsy syndromes are caused by their mutation. Here, we present a rare case of a seven-year-old female with co-occurrence of two genetic mutations in the pumilio homolog 1 ( PUM1 ) and sodium voltage-gated channel alpha subunit 2 ( SCN2A ).

show abstract

Efficacy of levetiracetam in the treatment of pediatric epilepsy

Cited by 2 publications

References 19 publications

Efficacy and Safety of Levetiracetam for Childhood Epilepsies

Efficacy and Safety of Levetiracetam for Childhood Epilepsies

Heterozygous Mutation of Sodium Voltage-Gated Channel Alpha Subunit 2 and Pumilio Homolog 1 Genes in a Pediatric Patient: A Case Report

Contact Info

Product

Resources

About